News

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]

In pediatric patients, the average treatment intensity was 22.8% of the maximum stimulator intensity, with slightly lower intensity levels compared to previous studies in adolescents and adults.

MoMeNtum will evaluate the efficacy and safety of DNTH103, administered subcutaneously every two weeks over a 17-week period, followed by a 52-week open-label extension to collect additional safety and efficacy data.

Lecanemab, an antiamyloid medication, was previously approved for the treatment of AD in the US in June 2023.

Known as REVITALYZ, the double-blind, placebo-controlled study will assess the effect of once-nightly sodium oxybate on the primary end point of change in Epworth Sleepiness Scale over a 14-week period.

The professor of neurology and Diana Davis Spencer Foundation Chair at the Jackson Laboratory provided context on a presentation from AAIC 2024 highlighting the ways genetics can impact microglia function and its relation to Alzheimer disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The president at Fasikl and the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center talked about results from a pilot study assessing the Felix Neural AI wristband in patients with essential tremor. [WATCH TIME: 4 minutes]

Using plasma p-tau217 shows promise as an effective, less invasive pre-screening method for identifying amyloid-β positive individuals in Alzheimer disease clinical trials.

Neurology News Network. for the week ending August 3, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on disparities on stroke.

The chief medical officer and head of Research & Development at Cognition Therapeutics provided clinical insight on new phase 2 data and the mechanism of action of CT1812, a therapy in development for Alzheimer disease. [WATCH TIME: 5 minutes]

In addition to showing a slowed disease progression, TPN-101-treated patients had lowered levels of key biomarkers involving neurodegeneration and neuroinflammation.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 2, 2024.

The meeting with the American Neurologic Association fosters collaboration, networking, and joint sessions, enhancing knowledge sharing among academic neurologists.

Enrollment in the dose level 2 expansion cohort is expected to complete early in Q3 2024, with initial strength and functional data anticipated in the second half of 2024.

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS talked about a recent study that examined the varying methods and results of clinical trials assessing the duration and efficacy of botulinum toxin treatment in cervical dystonia. [WATCH TIME: 7 minutes]

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

The 3-year data highlighted the safety profile of lecanemab and its disease-modifying effects on tau accumulation and other biomarkers related to AD pathology.

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of the use of erenumab, an FDA-approved medication for migraine, and the interactions between CGRP and orexin.

In this episode, the panel discusses the emerging challenges for neurology departments, the shortage of neurologists, and the ways to disseminate between useful and useless information amid a busy career.

The use of a blood test significantly improved diagnostic accuracy compared with standard clinical evaluations for Alzheimer disease, especially in primary and secondary care settings.

The vice president of scientific engagement at Alzheimer's Association talked about recent studies that highlight the progress made in blood biomarker tests for diagnosis, the impact of air pollution on brain health, and promising treatments for Alzheimer disease. [WATCH TIME: 8 minutes]

Although the primary endpoint of cerebral glucose metabolic rate change was not met, secondary endpoints showed significant benefits in brain volume and cognitive measures, further supporting the potential of GLP-1 agonists in AD.

CT1812, a sigma-2 receptor ligand, showed favorable changes in biomarkers like Aß40, Aß42, and neurofilament light (NfL), indicating its potential as a synaptoprotective agent.

Higher MIND diet scores correlate with larger hippocampal volume in older adults, suggesting potential benefits for brain health.

John England, MD, and Lisa Merlin, MD, commented on the significant changes to neurology over the years and how education aligns with the latest in treatments advancements and understanding of neurological disorders.

To ensure participant safety, all boys who received the gene therapy in the clinical program will be followed up for long-term safety monitoring.

A study recently presented at AAIC 2024 showed that higher consumption of processed red meat significantly increased the risk of dementia and cognitive decline among adults in the United States.

The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.